Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $959000.0.

  • X4 Pharmaceuticals' Other Non-Current Liabilities fell 9135.02% to $959000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $959000.0, marking a year-over-year decrease of 9135.02%. This contributed to the annual value of $13.8 million for FY2024, which is 1229.36% down from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Other Non-Current Liabilities is $959000.0, which was down 9135.02% from $535000.0 recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $47.2 million in Q2 2023 and a low of $312000.0 during Q3 2022
  • Its 5-year average for Other Non-Current Liabilities is $10.3 million, with a median of $2.9 million in 2025.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 1492515.92% in 2023, and later tumbled by 9419.93% in 2025.
  • X4 Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $826000.0 in 2021, then surged by 2502.91% to $21.5 million in 2022, then dropped by 27.06% to $15.7 million in 2023, then decreased by 12.29% to $13.8 million in 2024, then crashed by 93.03% to $959000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $959000.0 for Q3 2025, versus $535000.0 for Q2 2025 and $2.9 million for Q1 2025.